Meeting
2022 ASCO Annual Meeting
C-POST protocol update: A phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).
Authors
Danny Rischin
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
Danny Rischin , Daniel Brungs , Fiona Day , Hayden Robert Christie , Vishal A. Patel , Gerard Adams , James Estes Jackson , Maite De Liz Vassen Schurmann , Dmitry Kirtbaya , Thuzar M. Shin , Christopher David Hart , Elizabeth Stankevich , Siyu Li , Israel Lowy , Hyunsil Han , Matthew G. Fury , Sandro Porceddu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03969004
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9592)
DOI
10.1200/JCO.2022.40.16_suppl.TPS9592
Abstract #
TPS9592
Poster Bd #
183b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).
First Author: Danny Rischin
Poster
2019 ASCO Annual Meeting
KEYNOTE-630: Phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma.
First Author: Jessica Lyn Geiger
Poster
2014 ASCO Annual Meeting
ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).
First Author: Tae Gyun Kwon
Poster
2013 ASCO Annual Meeting
Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial.
First Author: Paul E. Goss